He did that to help certain individual during active trading hrs, The fact is TOTALLY OPPOSITE.
Gleevec, developed by Novartis and approved in 2001, inhibits the action of that errant protein. It turned chronic myeloid leukemia from a death sentence into a chronic disease for many patients and is still considered the paragon of molecularly targeted drugs. Global sales were $4.7 billion in 2011.
But about 20 to 30 percent of patients have cancers that do not respond to Gleevec or that develop resistance to it.
So companies developed other drugs — Tasigna from Novartis and Sprycel from Bristol-Myers Squibb — that also inhibit the aberrant protein but work in many of the cases that are resistant to Gleevec. But some cases do not respond to those drugs, either.
Iclusig was designed by chemists and computers at Ariad to work against cancer cells with a mutation — known as T315I — that makes them resistant to Gleevec, Tasigna and Sprycel.
However, Iclusig was approved not only for patients with that mutation but for any patient who has tried one of the other three drugs without success
his"Research Paper" full of sarcastic words for those who have been working so hard for so many years trying to develop life saving drugs, he was so happy and so certain like an "expert" that the drug "will not work, has no value"
What a way to make a living!